Information Provided By: 
Fly News Breaks for November 1, 2017
BCR, BDX
Nov 1, 2017 | 13:01 EDT
Piper Jaffray analyst William Quirk says that post CareFusion, Becton Dickinson is "swaying away from a consistent beat-and-raise story." His remarks follow CareFusion international website checks that continued to suggest little new outside the U.S. product launches during the quarter. The analyst modestly lowered his Street-high Q4 revenue estimate and maintains an Overweight rating on Becton Dickinson with a $213 price target. He views the pending C.R. Bard (BCR) acquisition as "very attractive."
News For BDX;BCR From the Last 2 Days
There are no results for your query BDX;BCR
